Endeavour Speciality Chemicals (Endeavour) today announced the launch of new additions to its range of novel building blocks and reactive intermediates, including new compounds targeted at Oncology research, a focused selection for researchers studying Nanomaterials and an expansion of its offering of novel Thioamides. 

Thioamides in particular are of great interest to researchers working in the pharmaceutical industry, as they are a well established route to forming Thiazoles, a group of compounds with applications for research into many debilitating diseases. These include Auto-immune disorders, Cardiovascular disease and Cancer.  One of the major factors behind this interest is the recent discovery that it is likely to be the presence of the Thiazole ring itself which inhibits tumor growth in certain types of cancer and this revelation will further heighten the significance of this particular branch of chemistry. 

With the introduction of the new products, Endeavour will have added over 100 original compounds to its catalogue of over 950 products since the 2010 Informex USA event in San-Francisco. Designed for the synthesis of complex molecules, the majority of Endeavours' products are based on its core technologies of sulphur and heterocyclic chemistry and are often unavailable from other manufacturers.  The new, non-exclusive products will be available from stock in small packs (1g - 100g) for early stage R&D or larger quantities (100g - 100kg) for projects moving through the development stage. 

"We are constantly designing and developing innovative products to meet the demands of research and discovery scientists as well as looking at new applications for existing products," commented Endeavour Sales Manager Jordi Robinson. "The new oncology and nanomaterials offers illustrate the diversity of our capabilities across a wide range of market segments and our development of additional novel thioamides shows our determination to remain at the forefront of current research thinking." 

Endeavour's products have applications across industry sectors, including pharmaceuticals, agrochemicals and materials sciences. Together with parent company, Robinson Brothers, Endeavour can support projects from initial development through to full-scale commercial production. 

Robinson Brothers and Endeavour have extensive experience in both Sulphur and Heterocyclic chemistries and the company is also recognised as a market leader in Hydrogenation technology.

For further information please visit  www.endeavourchem.co.uk